May 10, 2017 / 11:40 AM / 2 months ago

BRIEF-Proteon says receives FDA breakthrough therapy designation for vonapanitase

1 Min Read

May 10 (Reuters) - Proteon Therapeutics Inc

* Proteon therapeutics receives fda breakthrough therapy designation for vonapanitase

* Proteon therapeutics inc- enrollment in patency-2 trial is expected to complete in q1 of 2018

* Proteon therapeutics inc- proteon expects to report top-line data in q1 of 2019

* Proteon therapeutics inc- proteon also expects to submit a bla to fda in 2019.

* Proteon therapeutics inc - proteon also expects to submit a bla to fda in 2019 Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below